ACADIA PHARMACEUTICALS INC — Director's Dealing 2021

Oct 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-10-15

Reporting Person: DAVIS STEPHEN (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-15	Common Stock	M	5938	—	Acquired	55869	Direct
2021-10-18	Common Stock	S	2963	$17.41	Disposed	52906	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-15	Restricted Stock Units	$	M	5938	Disposed		Common Stock (5938)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: Includes 619 shares of the Issuer's common stock acquired by the reporting person on May 14, 2021 pursuant to an employee stock purchase program.

F3: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F4: The restricted stock units vest in four equal annual installments beginning 10/15/19.